Legacy Pharma has acquired InterMune and the rights to Esbriet® from Genentech to expand its specialty pharmaceutical portfolio and enhance patient access to treatments for idiopathic pulmonary fibrosis in the U.S.

Target Information

Legacy Pharma Inc. SEZC, commonly referred to as Legacy Pharma, is a specialty pharmaceutical company based in George Town, Cayman Islands. The company has aimed to enhance its portfolio by acquiring high-quality medications that cater to significant health needs. Recently, Legacy Pharma completed the acquisition of InterMune, Inc., alongside obtaining the intellectual property rights to Esbriet® (pirfenidone) in the United States from Genentech, a subsidiary of the Roche Group.

This acquisition emphasizes Legacy Pharma's commitment to ensuring access to innovative treatments for patients while maximizing therapeutic options in the pharmaceutical market. Esbriet® is specifically designed for patients suffering from idiopathic pulmonary fibrosis (IPF), a serious lung disease that currently lacks sufficient treatment alternatives, making this acquisition particularly strategic for the company's growth.

Industry Overview

The pharmaceutical industry in the United States is one of the most advanced and profitable sectors globally. It is characterized by continuous innovation, significant investment in research and developm